S1442
Interdisciplinary - Other
ESTRO 2026
Nicola Lambri 1,2 , Łukasz Kuncman 3 , Lisa Wiersema 4 , Francesca Romana Giglioli 5 , Per Munck af Rosenschöld 6,7 , Stefano Arcangeli 8,9 , Sarah Barrett 10 , Sophie Boisbouvier 11,12 , Tom Depuydt 13,14 , Patricia Diez 15,16 , Suraiya R. Dubash 17 , Maria A. Hawkins 18 , Coen Hurkmans 19 , Joerg Lehmann 20,21 , Giuseppe Minniti 22,23 , Filipe Moura 24 , Michel Ollers 25 , Miguel A. Palacios 26 , Marta Scorsetti 1,27 , Angela van Baardwijk 28 , Dirk Verellen 29,30 , Marta Bogowicz 31 , Antony Carver 32 , Stephanie Tanadini-Lang 31 , Pietro Mancosu 1,27 1 Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, Italy. 2 Scuola di Specializzazione in Fisica Medica, Università degli Studi di Milano, Milan, Italy. 3 Department of Radiotherapy, Medical University of Lodz, Łódź, Poland. 4 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands. 5 Medical Physics Unit, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy. 6 Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 7 Medical Radiation Physics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. 8 Medicine and Surgery Department, University Milano-Bicocca, Milan, Italy. 9 Radiation Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. 10 Applied Radiation Therapy Trinity, Trinity St. James’s Cancer Institute, Discipline of Radiation Therapy, Trinity College, Dublin, Ireland. 11 Radiation Oncology Department, Centre Léon Bérard, Lyon, France. 12 UMR Inserm 1052 CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France. 13 KU Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium. 14 Department of Radiation Oncology, UZ Leuven, Leuven, Belgium. 15 Clinical Physics Department, National Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom. 16 Clinical Physics Department, Mount Vernon Cancer Centre, Northwood, United Kingdom. 17 Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom. 18 Medical Physics and Biomedical Engineering, University College, London, United Kingdom. 19 Department of Radiation Oncology, Catharina Ziekenhuis, Eindhoven, Netherlands. 20 School of Information and Physical Sciences, University of Newcastle, Newcastle, Australia. 21 Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, Australia. 22 Radiation Oncology, Policlinico Umberto I, Rome, Italy. 23 Department of Radiological, Oncological and Pathological Sciences, “Sapienza” University of Rome, Rome, Italy. 24 CrossI&D Lisbon Research Center, Portuguese Red Cross Higher Health School Lisbon, Lisbon, Portugal. 25 Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht, Netherlands. 26 Department of Radiation Oncology,
Amsterdam UMC, Amsterdam, Netherlands. 27 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. 28 Radiation Oncology, Maastro, Maastricht, Netherlands. 29 Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium. 30 Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium. 31 Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. 32 Department of Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom Purpose/Objective: Stereotactic body radiation therapy (SBRT/SABR) is increasingly utilized across multiple anatomical sites, with implementation described in site-specific guidelines. However, the fundamental technical requirements of SBRT/SABR are largely independent of the treatment site [1]. This systematic review aimed to provide a comprehensive overview of reported technical requirements for performing extra-cranial SBRT/SABR irrespective of anatomical region. Material/Methods: A systematic review of randomized phase 3 studies was performed and reported in accordance with the PRISMA guidelines [2]. Eligible studies included at least one SBRT/SABR arm, excluding SBRT/SABR delivery with protons. PubMed was searched on 2 December 2024 to identify records published between January 2014 and December 2024. Additional records were found mainly through websites search. An ESTRO writing panel was divided into five thematic groups: Patient Simulation and Setup; Treatment Planning and Delivery; Image Guidance and Verification; Motion Management; Machine QA and Safety Measurements. Each group included at least one radiation oncologist, medical physicist, and radiation therapist. Relevant data fields were agreed by all groups prior to extraction. Results: Fourteen phase 3 studies were identified, covering a range of extra-cranial primary indications including lung, liver, spine, prostate, and oligometastatic disease. Data were extracted from the available study reports and corresponding trial protocols (Figure 1). A total of 73 relevant data fields and 1022 entries were collected according to the five thematic groups; 31 data fields are summarised in Figure 2. Over half (56%) of the expected information was missing from both reports and protocols. Dose prescription, treatment machine type, staff roles and responsibilities, and risk assessment were consistently reported (14/14). In contrast, limited information was available for simulation CT parameters – field of view (0/14), in- plane resolution (0/14), and scan range (5/14) – as well as for MLC leaf width (2/14), dose rate (0/14), delivery
Made with FlippingBook - Share PDF online